Browse by author
Lookup NU author(s): Raheel Ahmed
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.Despite advances in percutaneous coronary procedures, in-stent restenosis remains a significant challenge. Although sirolimus- and paclitaxel-coated balloons are promising alternatives, but their comparative safety and efficacy remain uncertain. PubMed, Embase and Cochrane databases were searched using relevant keywords from inception until August 2025. A total of 11 studies (7 RCTs and 4 observational cohort studies) were included, comprising 3, 633 participants overall. The primary outcomes assessed were target lesion revascularization (TLR) and target lesion failure (TLF). Meanwhile, the Secondary outcomes included stent thrombosis, all-cause mortality, myocardial infarction, major adverse cardiovascular events (MACE), survival, binary restenosis, and angiographic endpoints (acute gain, diameter stenosis, in-segment late lumen loss, in-lesion late lumen loss, and in-segment minimal lumen diameter). Interstudy heterogeneity was assessed using I2 and X2 statistics (I2>50%=significant heterogeneity). Interstudy heterogeneity was low for most outcomes, including all primary clinical endpoints, with moderate heterogeneity observed only for select angiographic measures (notably in-segment late lumen loss and diameter stenosis). Statistical calculations were performed using Review Manager 5.4.1, with a p-value of < 0.05 indicating statistical significance.This meta-analysis examined studies that compared paclitaxel-coated balloon (PCB) versus standard balloon (SCB) angioplasty. Regarding primary outcomes, there were no notable variations in target lesion failure (RR 1.08, 95% CI 0.90–1.29, p=0.36) or target lesion revascularization (RR 1.16, 95% CI 0.98–1.37, p=0.08). With all aggregated estimates being nonsignificant, secondary outcomes such as stent thrombosis, all-cause mortality, myocardial infarction, MACE, and survival were similar between groups. Angiographic endpoints revealed no discernible variations in late lumen loss (in-lesion and in-segment), acute gain, or diameter stenosis. Nonetheless, the SCB group's minimal lumen diameter was significantly smaller than that of the PCB group (MD –0.08 mm, 95% CI –0.14 to –0.01, p=0.02). In treating coronary ISR, sirolimus- and paclitaxel-coated balloons show similar overall safety and effectiveness; lesion-specific angiographic variations indicate that customized selection may improve patient outcomes.
Author(s): Sajjad F, Khattak AI, Farhan K, Arshad A, Afridi A, Ali MA, Shahid I, Imtiaz Z, Naveed H, Alam U, Henna F, Riaz Z, Khattak F, Waqas SA, Ahmed R
Publication type: Review
Publication status: Published
Journal: Critical Pathways in Cardiology
Year: 2026
Pages: Epub ahead of print
Online publication date: 07/01/2026
Acceptance date: 02/04/2018
ISSN (print): 1535-282X
ISSN (electronic): 1535-2811
Publisher: Lippincott Williams and Wilkins
URL: https://doi.org/10.1097/HPC.0000000000000415
DOI: 10.1097/HPC.0000000000000415
PubMed id: 41533835
